990x120 July 2-3

Event Overview

Several biotech and pharmaceutical companies have joined forces to investigate the molecular mechanisms of SARS-CoV-2 infection and to identify targets for medicines and vaccines. As members of the Seattle Consortium, IsoPlexis, Merck, and the Institute for Systems Biology play key roles in the search for COVID-19 prognostic immune biomarkers. In this webinar sponsored by IsoPlexis, James Heath from the Institute for Systems Biology and Stacey Willard from IsoPlexis will discuss how functional phenotyping individual immune cells using IsoPlexis technology edges researchers closer to predicting the risk for severe disease.

Topics to be covered
  • Proteomic and genomic insights into COVID-19
  • Mapping functional immune responses at the single-cell and serum level to study COVID-19
  • Using single-cell proteomics to study how to create a balanced and durable immune response in COVID-19 patients and assist efforts to create future vaccines and therapies
Thursday, July 2, 2020
3:30 - 5:00 PM, Eastern Standard Time


James R. Heath, PhD
President and Professor
Institute for Systems Biology, Seattle

Stacey Willard, PhD
Product Manager


Register Now

Single-Cell Proteomics Reveal Immune Responses to COVID-19: Proteomic and Genomic Findings from the Seattle Consortium

You must have Javascript and Cookies enabled to access this webcast.

Information you provide will be held in confidence and will be shared with the sponsoring vendor(s) of this webinar. We may use the information to contact you about your account and to let you know about related programs and products; you may opt-out at any time. This allows The Scientist to keep these webinars free of charge for our readers.